# A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

> **NCT07036185** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Bao Pharmaceuticals Co., Ltd.** · enrollment: 66 (estimated)

## Conditions studied

- Gastric/Gastroesophageal Junction Cancer
- Breast Cancer
- Colorectal Cancer
- Non-small Cell Lung Cancer (NSCLC)
- Bile Duct Cancer
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** KJ015 Injection (Subcutaneous Injection)

## Key facts

- **NCT ID:** NCT07036185
- **Lead sponsor:** Shanghai Bao Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-24
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-04-30
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07036185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07036185, "A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07036185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*